login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
SEER INC (SEER) Stock News
NASDAQ:SEER - Nasdaq -
US81578P1066
-
Common Stock
- Currency: USD
2.19
+0.07 (+3.3%)
Summary
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SEER Latest News, Press Relases and Analysis
All
Press Releases
2 days ago - By: Seer, Inc.
Seer to Report Second Quarter 2025 Financial Results on August 6, 2025
2 days ago - By: Seer, Inc.
Seer to Report Second Quarter 2025 Financial Results on August 6, 2025
2 months ago - By: Seer, Inc.
Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
2 months ago - By: Seer, Inc.
Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
5 months ago - By: Benzinga
- Mentions:
SSP
CLCO
CVEO
DCI
...
Earnings Scheduled For February 27, 2025
2 months ago - By: Seer, Inc.
Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency
2 months ago - By: Seer, Inc.
Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency
2 months ago - By: Seer, Inc.
Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
2 months ago - By: Seer, Inc.
Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
2 months ago - By: Zacks Investment Research
- Mentions:
CTMX
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates
3 months ago - By: Zacks Investment Research
- Mentions:
RPRX
Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates
3 months ago - By: Zacks Investment Research
- Mentions:
ANAB
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
2 months ago - By: Benzinga
- Mentions:
ICMB
IRIX
KLC
ONON
...
Earnings Scheduled For May 13, 2025
3 months ago - By: Seer, Inc.
Seer to Report First Quarter 2025 Financial Results on May 13, 2025
3 months ago - By: Seer, Inc.
Seer to Report First Quarter 2025 Financial Results on May 13, 2025
5 months ago - By: Seer, Inc.
Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook
5 months ago - By: Seer, Inc.
Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook
5 months ago - By: Seer, Inc.
Seer to Participate in the TD Cowen 45th Annual Health Care Conference
5 months ago - By: Seer, Inc.
Seer to Participate in the TD Cowen 45th Annual Health Care Conference
5 months ago - By: Seer, Inc.
Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025
5 months ago - By: Seer, Inc.
Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
5 months ago - By: Seer, Inc.
Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
5 months ago - By: Seer, Inc.
Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025
7 months ago - By: Seer, Inc.
Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference
7 months ago - By: Seer, Inc.
Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference
8 months ago - By: Seer, Inc.
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
8 months ago - By: Seer, Inc.
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
9 months ago - By: Seer, Inc.
Seer to Participate in Upcoming November Investor Conferences
9 months ago - By: Seer, Inc.
Seer to Participate in Upcoming November Investor Conferences
9 months ago - By: Seer, Inc.
Seer Reports Third Quarter 2024 Financial Results
9 months ago - By: Seer, Inc.
Seer Reports Third Quarter 2024 Financial Results
9 months ago - By: Seer, Inc.
Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
9 months ago - By: Seer, Inc.
Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
9 months ago - By: Seer, Inc.
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024
9 months ago - By: Seer, Inc.
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024
9 months ago - By: Seer, Inc.
Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer’s, Population Health, and Xenotransplantation at HUPO 2024
9 months ago - By: Seer, Inc.
Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer’s, Population Health, and Xenotransplantation at HUPO 2024
9 months ago - By: Seer, Inc.
Seer to Report Third Quarter 2024 Financial Results on November 6, 2024
9 months ago - By: Seer, Inc.
Seer to Report Third Quarter 2024 Financial Results on November 6, 2024
Please enable JavaScript to continue using this application.